MedTrace Logo

Clinical Trial to Evaluate the Potential Efficacy and Safety of Human Umbilical Cord Blood and Plasma

NCT02418013 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2016-01-13

No results posted yet for this study

Summary

This study aims to carry out a safety evaluation of human cord blood and frozen plasma as treatment for pre-frailty , to assess whether the treatment can prevent and improve the aging process, and to identify useful clinical markers of frailty.

The study is a randomized, double-blinded and placebo-controlled pilot clinical Trial conducted at CHA clinical trial institute.

Conditions

  • Aging

Interventions

OTHER

Fresh cord blood(experimental group A)

1. Cord blood is administered through intravenous at CHA clinical trail institute. 2. Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered prior to the treatment.

OTHER

Frozen cord blood(experimental group B)

1. Cord blood is administered through intravenous at CHA clinical trail institute. 2. Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered

OTHER

Frozen plasma(experimental group C)

1. Cord blood is administered through intravenous at CHA clinical trail institute. 2. Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered

OTHER

Placebo group

A placebo agent is administered through intravenous at CHA clinical trail institute. It should be certain that when administered, participants are not aware of which treatments are preformed.

Sponsors & Collaborators

  • Bundang CHA Hospital

    lead OTHER

Principal Investigators

  • Myung Ryool Park, PhD · orthopedics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2017-08-31
Completion
2017-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02418013 on ClinicalTrials.gov